Luoxin Pharmaceuticals Group Stock Co., Ltd. (SHE:002793)
China
· Delayed Price · Currency is CNY 5.54
+0.15 (2.78%)
Apr 30, 2026, 1:55 PM CST
SHE:002793 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Net Income | -270.08 | -288.58 | -965.5 | -661.14 | -1,225 | 406.1 | Upgrade
|
| Depreciation & Amortization | 204.12 | 204.12 | 205.79 | 208.29 | 231.31 | 199.78 | Upgrade
|
| Other Amortization | 12.21 | 12.21 | 5.81 | 14.25 | 42.06 | 12.46 | Upgrade
|
| Loss (Gain) From Sale of Assets | -3.08 | -3.08 | -0.24 | 12.18 | -1.74 | 3.31 | Upgrade
|
| Asset Writedown & Restructuring Costs | 31.34 | 31.34 | 229.97 | 56.64 | 93.09 | 103.44 | Upgrade
|
| Loss (Gain) From Sale of Investments | 49.06 | 49.06 | 3.45 | -15.05 | -168.31 | 2.18 | Upgrade
|
| Provision & Write-off of Bad Debts | -46.89 | -46.89 | 14.12 | 54.97 | - | - | Upgrade
|
| Other Operating Activities | 99.09 | 132.45 | 264 | 37.73 | 99.18 | 120.1 | Upgrade
|
| Change in Accounts Receivable | 33.48 | 33.48 | -17.52 | 791.71 | 689.64 | -733.09 | Upgrade
|
| Change in Inventory | 81.29 | 81.29 | -79.29 | 168.47 | -52.04 | -70.37 | Upgrade
|
| Change in Accounts Payable | 27.56 | 27.56 | 81.46 | -365.76 | -383.63 | 139.91 | Upgrade
|
| Change in Other Net Operating Assets | 26.31 | 26.31 | 2.57 | 27.27 | - | -5.56 | Upgrade
|
| Operating Cash Flow | 238.2 | 253.07 | -157.85 | 466.89 | -939.13 | 120.63 | Upgrade
|
| Operating Cash Flow Growth | 151.24% | - | - | - | - | - | Upgrade
|
| Capital Expenditures | -30.7 | -32.18 | -115.35 | -242.39 | -194.82 | -309.03 | Upgrade
|
| Sale of Property, Plant & Equipment | 3.66 | 3.8 | 5.32 | 6.85 | 3.07 | 2.13 | Upgrade
|
| Cash Acquisitions | - | - | - | - | -1.93 | -4.58 | Upgrade
|
| Divestitures | 136.31 | 104.17 | 101.65 | - | -8.73 | - | Upgrade
|
| Investment in Securities | 25.23 | 25.23 | 5.1 | 98.7 | 65.35 | -81.55 | Upgrade
|
| Other Investing Activities | 25.04 | 23.04 | 1.95 | 1,094 | 17.87 | -35.39 | Upgrade
|
| Investing Cash Flow | 159.54 | 124.06 | -1.34 | 957.43 | -119.18 | -428.42 | Upgrade
|
| Long-Term Debt Issued | - | 996.99 | 1,034 | 1,028 | 2,254 | 1,459 | Upgrade
|
| Long-Term Debt Repaid | - | -1,295 | -890.71 | -3,277 | -2,312 | -873.92 | Upgrade
|
| Net Debt Issued (Repaid) | 0.78 | -298.22 | 142.96 | -2,249 | -58.44 | 585.14 | Upgrade
|
| Issuance of Common Stock | 23.28 | 23.28 | 36.99 | - | - | - | Upgrade
|
| Repurchase of Common Stock | - | - | -100 | - | -40.66 | -30.14 | Upgrade
|
| Common Dividends Paid | -46.97 | -48.98 | -61.19 | -76.78 | -138.26 | -132.33 | Upgrade
|
| Other Financing Activities | -63.28 | -11.1 | -152.88 | 644.73 | 622.35 | 366.86 | Upgrade
|
| Financing Cash Flow | -86.18 | -335.02 | -134.13 | -1,681 | 384.98 | 789.53 | Upgrade
|
| Foreign Exchange Rate Adjustments | -2.8 | -1.23 | 2.76 | 2.18 | 14.1 | -1.13 | Upgrade
|
| Net Cash Flow | 308.76 | 40.88 | -290.55 | -254.41 | -659.23 | 480.61 | Upgrade
|
| Free Cash Flow | 207.5 | 220.88 | -273.2 | 224.5 | -1,134 | -188.4 | Upgrade
|
| Free Cash Flow Margin | 8.74% | 9.72% | -10.32% | 9.50% | -31.61% | -2.91% | Upgrade
|
| Free Cash Flow Per Share | 0.20 | 0.21 | -0.26 | 0.21 | -0.80 | -0.13 | Upgrade
|
| Cash Income Tax Paid | 196.77 | 186.23 | 102.04 | -7.95 | 581.21 | 645.92 | Upgrade
|
| Levered Free Cash Flow | 376.41 | 243.97 | 45.12 | 1,338 | -623.17 | -626.37 | Upgrade
|
| Unlevered Free Cash Flow | 411.15 | 278.71 | 85.36 | 1,386 | -546.5 | -560.63 | Upgrade
|
| Change in Working Capital | 162.44 | 162.44 | 84.75 | 759.01 | -9.79 | -726.73 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.